Kura Oncology (NASDAQ:KURA) Stock Rating Lowered by StockNews.com

Kura Oncology (NASDAQ:KURA) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other brokerages also recently commented on KURA. JMP Securities reissued a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Thursday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Scotiabank reduced their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group reduced their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Stock Down 1.0 %

Shares of NASDAQ:KURA opened at $7.27 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market capitalization of $587.09 million, a PE ratio of -3.08 and a beta of 0.85. The business has a 50 day simple moving average of $7.81 and a two-hundred day simple moving average of $12.61. Kura Oncology has a 1 year low of $6.79 and a 1 year high of $23.48.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. On average, equities analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC lifted its stake in Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares in the last quarter. Point72 DIFC Ltd purchased a new position in Kura Oncology in the 3rd quarter worth approximately $146,000. Harbor Advisors LLC purchased a new position in Kura Oncology in the 4th quarter worth approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the 4th quarter worth approximately $90,000. Finally, Erste Asset Management GmbH purchased a new position in Kura Oncology in the 3rd quarter worth approximately $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.